He has extensive training in clinical pharmacology and drug development, with specific expertise in clinical pharmacokinetics/pharmacodynamics (PK/PD). He has also performed preclinical studies to better inform the exposure-safety relationships of certain drugs. These works have propelled my understanding and passion for the design of safer and more effective treatment regimens in special populations, who are often excluded during drug development.